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ABSTRACT
Chemotherapy with anticancer drugs is known to be beneficial, but like a double-edged sword, it has its own demerits in the form of adverse effects. 
Cancer chemotherapy-induced thrombocytopenia is troublesome, and platinum-based regimens, namely carboplatin and cisplatin, are known to 
cause it very commonly. Gemcitabine, in combination with platinum compounds, is known to cause severe thrombocytopenia. Hence, we report a case 
of thrombocytopenia induced by gemcitabine when used as a single agent in the treatment of ovarian cancer.
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INTRODUCTION
Gemcitabine is used in the treatment of several solid tumors. Despite its 
very high antitumor activity, the adverse effects due to chemotherapy 
with gemcitabine always play a spoil sport. It is used in the treatment 
of various cancers such as ovarian, breast, and pancreatic malignancies 
and it acts by inhibiting the growth of cancer cells which is proven in 
many clinical trials as well as by in vivo and in vitro tumor models [1]. 
It causes various adverse effects ranging from nausea, vomiting, hair 
loss, diarrhea, myelosuppression, weakness, anemia, and so on. Hence, 
we report a case of gemcitabine-induced thrombocytopenia in a 
52-year-old female diagnosed of ovarian malignancy.
CASE REPORT
A 52-year-old female patient diagnosed of metastatic ovarian 
carcinoma underwent cytoreduction surgery and was started on 
gemcitabine-based chemotherapy post-surgery. Informed consent was 
obtained from the patient. As on September 07, 2015, the patient had 
received three cycles of chemotherapy, and 1 week after the third cycle 
on September 14, 2015, the patient developed severe fall in platelet 
counts. The patient also had elevated blood urea nitrogen (46 mg/dl). 
Before the start of the third cycle, platelet counts were normal. Other 
system examination was normal, and there was no other abnormality. 
All the other causes of thrombocytopenia including infections, other 
concomitant medications causing fall in platelet counts were ruled out, 
and gemcitabine was suspected to be the causative agent. No specific 
treatment was given, and the patient recovered back with normal 
platelets on September 9, 2015 (Table 1), before the start of the next 
chemotherapy cycle.
DISCUSSION
Gemcitabine hydrochloride with a molecular formula of C9H11F2N3O4. 
HCL is a 2’-deoxy-2’, 2’-difluorocytidine monohydrochloride. It is a white 
powder with a PKa of 3.6, soluble in water and methanol, but insoluble 
in alcohol [1]. It was initially investigated as an antiviral agent but soon 
claimed its place as an effective antitumor agent. Now, in medical field, 
gemcitabine is used in the treatment of bladder cancers, non-small cell 
lung cancer, and metastatic pancreatic cancer as a single agent. It is also 
used in combination chemotherapy with other anti-cancer agents in the 
treatment of ovarian cancer and breast cancer. Gemcitabine, a cytidine 
analog, is a prodrug and it requires phosphorylation to generate 
active metabolites. The active metabolite of gemcitabine which is 
gemcitabine triphosphate gets incorporated into deoxyribonucleic 
acid (DNA) and acts by stopping the DNA chain elongation by inhibiting 
DNA polymerase enzyme. Recent evidence also reports that it acts by 
poisoning topoisomerase I and results in breakage of DNA strand [2].
As cancer therapy is always known to cause side effects, gemcitabine 
is not indifferent. It causes various side effects including nausea, 
vomiting, hair loss, myelosuppression, skin rashes, and even 
lung toxicity. Thrombocytopenia is a very common side effect 
of cancer therapy and usually cancer regimens associated with 
thrombocytopenia include anthracycline-based regimens and taxane-
based regimens including cisplatin and carboplatin. In one adverse 
drug assessment study in India, it was noted that thrombocytopenia 
occurs in 6.6% in males and 11.2% in females receiving anticancer 
treatment [3]. In other study, thrombocytopenia occurred in 82% 
of those receiving only carboplatin, and in 58%, 64%, and 59% of 
those receiving combination therapies with carboplatin, gemcitabine, 
or paclitaxel, respectively [4]. In one systemic review, it was found 
that gemcitabine as a single agent causes 7.8% and 3.4% of Grade 3 
and Grade 4 thrombocytopenia, respectively [5]. The most common 
mechanism associated with gemcitabine-induced thrombocytopenia 
is direct myelosuppression and thrombotic microangiopathy which 
is often referred to as hemolytic uremic syndrome. However, usually, 
chemotherapy-induced thrombocytopenia has various confounding 
factors which include the solid organ tumor itself contributing to 
thrombocytopenia, immune-mediated thrombocytopenia, infection-
associated, concomitant administration of drugs such as heparin, 
vancomycin, valganciclovir, post-blood transfusion-associated 
drop in platelet counts, and chemotherapy-associated thrombotic 
microangiopathy [5].
In our case, all the other causes of thrombocytopenia were ruled 
out, and gemcitabine was found to be the causative agent. More to 
it, platelet counts reached a nadir after 7 days of last chemotherapy 
cycle and returned to normal levels after 14 days [5]. Hence, it also 
supports gemcitabine to be suspected as the causative factor. Hence, 
to establish causative relationship between adverse effect and drug 
(Table 2), causality assessment was done using Naranjo’s scale [6] and 
a probable causal relationship was ascribed. Severity assessment was 
done using Hartwig’s scale [7] and adverse effect was found to be of 
mild severity. Adverse drug reaction was found to be not preventable 
using Thornton’s preventability scale [8].
CONCLUSION
Since gemcitabine is a single-agent chemotherapy used in the 
treatment of many solid organ tumor, monitoring of thrombocytopenia 
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associated with it is very important as it may be one of the presenting 
features of hemolytic uremic syndrome. Hence, further prospective 
studies are warranted to find the incidence of thrombocytopenia 
in solid organ cancer patients’ treatment with gemcitabine-based 
regimens.
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Table 1: Platelet counts before and after third cycle
Date Platelet counts/mm3
September 04, 2015 1.8 lakhs
September 14, 2015 1.1 lakhs
September 19, 2015 4.1 lakhs
Table 2: Adverse drug assessment
Scaling Assessment
Naranjo’s Probable
Hartwig’s Mild severity
Thornton’s Not preventable
